Fig. 1 · Structure
Documents & Downloads
Fuzapladib sodium
LFA-1 Activation Inhibitor
Fuzapladib sodium is an orally active inhibitor of leukocyte-function-associated antigen type 1 (LFA-1) activation, functioning primarily as a leukocyte adhesion molecule modulator. It also acts as a phospholipase A2 (PLA2) inhibitor, contributing to its anti-inflammatory properties. Fuzapladib sodium is utilized in research focused on understanding and mitigating leukocyte migration in inflammatory conditions.
In Stock
Free Aliquoting for Your Order
Tell us your preferred amount per vial. We’ll confirm the options.
Specifications
| Manufacturer | Adooq Bioscience |
|---|---|
| Actions | Inhibitor |
| CAS Number | 141284-73-3 |
| Applications | LFA-1 Activation Inhibitor |
| Formula | C15H20F3N3NaO3S |
| Molecular Weight | 402.39 |
| Synonyms | IS-741 sodium |
| SMILES | O=C(C1CCCCC1)NC2=CC(C(F)(F)F)=CN=C2NS(=O)(CC)=O.[Na] |
Storage & Solubility
In Vitro Solubility
Reported Solubility
No reported solubility data are available for this product.
Preparing Stock Solutions
| Concentration | |
|---|---|
Values use four significant digits. Prepare to the final solution volume; this is not the volume of solvent to add.
Stock preparation is unavailable for this product molecular weight.
Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.
Storage
Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.